CompletedPHASE1, PHASE2NCT02349009
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prism Pharma Co., Ltd.
- Principal Investigator
- Robert Lafyatis, MDBoston University
- Intervention
- C-82 Topical Gel, 1%(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2016
Study locations (3)
- Chicago, Illinois, United States
- Boston, Massachusetts, United States
- New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02349009 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University